Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether adding modified-release dipyridamole
to aspirin (Asasantin Retard) has measurable effects on markers of platelet function (for
example, platelet aggregation) in patients with cardiovascular disease who are known to be
resistant to aspirin alone